Drug delivery
Precise.

A new system for fighting glioblastoma.

The Problem

Glioblastoma

The most common and aggressive brain cancer.

6%
5-Year Survival Rate
200K
Deaths per Year
$200K
Annual Cost per Patient
90%
2-Year Tumour Recurrence

Watch how Sanavo uses Microdevices
to deliver drugs precisely to brain tumors.

The Solution Part I

Hyaluronic Acid (HA) Nanogels

A safe and precise drug delivery solution
to improve patient survival rate for glioblastoma.

Injection

Via a small syringe into the vertebral arteries.

Navigation

With RBC hitchhiking & CD44 antibodies.

Drug Release

Triggered by the acidic environment of tumours.

Decomposition

Biodegrades programatically into sugar.




Hyaluronic Acid Nanogel Design

Our nanogel is made through reverse microemulsion crosslinking and uses 1,4-butanediol diglycidyl ether (BDDE) as our crosslinking agent, which is FDA approved. Finally, we conjugate polyethylene glycol in PEGylation.

  • - The drug (TMZ) is embedded inside and released during degradation
  • - A layer of PEG acts as protection and reduces interactions with blood proteins
  • - HA has antibodies for CD44, which is overexpressed on many tumour cells
Learn more





The Solution Part II

Poly(lactic-co-glycolic acid) (PLGA) Biosensors

A biodegradable, accurate, and non-invasive detection system
to combat tumour recurrence with improved imaging and early detection.

Binding

PLGA biosensors bind to RBCs ex vivo, forming an RBC-biosensor complex.

Navigation

Injection into vertebral arteries then crosses the BBB and the sensor is released.

Detection

Tumours trigger the production of H₂0₂ which can be easily detected with Cy7.

Decomposition

Biodegrade naturally into non-toxic metabolites after 1-2 years.




Biosensor Design

The sensor is made by emulsification-solvent evaporation (or nanoprecipitation) to form the PLGA core, the enzyme and Cy7 are encapsulated during nanoparticle formation. Finally, conjugate the CD47 antibodies onto the surface for RBC hitchhiking.

  • - The Cy7 reporter molecule binds to the CD47 protein on the Red Blood Cell (RBC)
  • - Due to reactions with excess glucose in the tumour, H₂0₂ is produced
  • - Via Cy7, a Near Infrared (NIR) fluorophore, H₂0₂ can be easily detected, indicating a recurrence
Learn more

Advantages

The main benefits of our HA-Nanogels in comparison to
traditional treatment and other microdevices.

Preciseness

HA has a natural affinity to the tumour cell protein CD44, preventing side effects and targeting delivery and release.

Biocompatability

RBC hitchhiking eases delivery, and HA nanogels are soft, stimuli-responsive, and biodegrade into sugar in a couple of days.

Load

Nanogels can incorporate 30% of their weight in numerous different biological molecules and drugs, which is unusually high.

FAQ

NO, surgery will still play a part to remove a majority of the tumor. Our solution replaces chemotherapy and radiation therapy, the second parts of glioblastoma treatement. While surgery removes a majority of the tumor, glioblastoma is not cured until every single cancer cell is removed. Thus, our solution solves the last but critical percent needed to treat glioblastoma.

Our belief is that our treatment needs to cost less than current treatment regimes, meaning that you are not only paying less but you also have a way higher chance of surviving.

The biosensors will be used before surgery to get a better image of the tumor so that surgeons can have a better picture of how they should proceed with surgery and after treatment is done, so that tumor recurrence can be spotted quickly.

© Sanavo 2024